Top 10 Companies in the Crystalline Fructose for Pharmaceutical Market (2026): Market Leaders Driving Global Pharmaceutical Excipients

MARKET INSIGHTS

The Global crystalline fructose for pharmaceutical market was valued at USD 108 million in 2024. The market is projected to grow from USD 115 million in 2025 to USD 166 million by 2031, exhibiting a CAGR of 6.5% during the forecast period.

Crystalline fructose is a highly purified monosaccharide sweetener derived primarily from corn starch or sucrose through hydrolysis. In pharmaceutical applications, it serves as an excipient in formulations due to its high solubility, low glycemic index, and enhanced stability compared to other sweeteners. The product exists in two primary forms: starch-based and sucrose-derived fructose, with starch hydrolysis being the dominant production method.

The market growth is driven by increasing pharmaceutical manufacturing activities, particularly in injectable formulations and medical supplements. While the broader pharmaceutical sector reached USD 1.47 trillion in 2022, biologics accounted for USD 381 billion of this total. Key players like Tate & Lyle and ADM are expanding production capacities to meet rising demand for high-purity fructose in parenteral nutrition and specialty medications. However, stringent regulatory requirements for excipient quality and fluctuating raw material prices present ongoing challenges for market participants.

Crystalline Fructose for Pharmaceutical Market – View in Detailed Research Report

Market Size Overview

The Global crystalline fructose for pharmaceutical market was valued at USD 108 million in 2024 and is projected to reach USD 166 million by 2031, growing at a CAGR of 6.5% during the forecast period.

Product Definition

Crystalline fructose is a pure, crystalline form of the sugar fructose that is engineered for pharmaceutical use. Its high purity (99.5%+), low glycemic index, and excellent solubility make it an attractive excipient for oral liquids, injectables, and nutritional supplements.

Top 10 Companies in the Crystalline Fructose for Pharmaceutical Market (2026)

---

🔟 1. Tate & Lyle PLC

Headquarters: Norwich, United Kingdom
Key Offering: Pharmaceutical‑grade crystalline fructose for injectable solutions and nutrition products

Tate & Lyle has leveraged its long‑standing expertise in sweetener production to secure a leading position in the pharmaceutical arena. The company’s supply chain spans from corn‑based starch processing to finished excipient, ensuring consistent quality across North America and Europe.

Sustainability & Growth Initiatives:

• Investing in low‑carbon processing technologies for starch hydrolysis
• Expanding production capacity in Asia‑Pacific to meet rising demand for parenteral nutrition
• Collaborating with pharmaceutical partners on next‑generation excipient formulations

---

🈸 2. ADM (Archer Daniels Midland)

Headquarters: Chicago, United States
Key Offering: High‑purity crystalline fructose for injection and medical supplement applications

ADM’s vertical integration from corn processing to refined sweetener production has positioned it as a reliable supplier for the growing pharmaceutical sector. Recent capacity expansions in the Asia‑Pacific region have strengthened its foothold in emerging markets.

Sustainability & Growth Initiatives:

• Optimizing energy use in starch hydrolysis units
• Implementing dual‑sourcing strategies to mitigate supply chain volatility
• Partnering with global pharma firms on customized excipient solutions

---

🈶 3. GALAM Group

Headquarters: Tel Aviv, Israel
Key Offering: Premium pharmaceutical‑grade fructose for medical supplements and specialty formulations

GALAM has carved out a niche by focusing on high‑purity fructose products, securing over 15% of the medical supplement market in 2024. Its emphasis on stringent quality control aligns with the strict regulatory environment of the pharmaceutical industry.

Sustainability & Growth Initiatives:

• Adopting eco‑friendly sourcing of raw materials
• Expanding R&D for fructose‑based excipients in nutraceuticals
• Strengthening API certification portfolio to support regulated markets

---

🈚 4. DANISCO (DuPont Nutrition & Biosciences)

Headquarters: Odense, Denmark
Key Offering: Specialty fructose products for pharmaceutical and nutraceutical applications

DANISCO’s focus on specialty fructose production, coupled with its global distribution network, has enabled it to serve a broad spectrum of pharmaceutical clients. The company is actively involved in developing customized excipients for niche therapeutic areas.

Sustainability & Growth Initiatives:

• Investing in continuous manufacturing to reduce production costs
• Enhancing supply chain resilience through strategic partnerships
• Exploring new applications in targeted drug delivery systems

---

🈷 5. Gadot Biochemical Industries

Headquarters: Tel Aviv, Israel
Key Offering: Custom fructose formulations for specialized pharmaceutical products

Gadot Biochemical has positioned itself as a specialist in tailored fructose excipients, supporting the development of advanced drug delivery platforms. Its focus on high‑purity standards meets the stringent demands of regulated markets.

Sustainability & Growth Initiatives:

• Developing low‑impact production processes for fructose synthesis
• Collaborating with pharma companies on clinical trials of fructose‑based delivery systems
• Expanding production capacity in the Middle East to serve regional markets

---

🈚 6. Xiwang Group

Headquarters: Shanghai, China
Key Offering: Cost‑effective crystalline fructose for injection and nutritional products

Xiwang Group has leveraged its domestic production base to offer competitively priced fructose solutions. The company has been upgrading its quality control systems to meet international pharmacopeia standards.

Sustainability & Growth Initiatives:

• Investing in advanced purification technologies to enhance product purity
• Expanding API certification to support regulated markets
• Developing regional supply chains to reduce import dependencies

---

🈚 7. Hebei Huaxu Pharmaceutical Co., Ltd.

Headquarters: Shijiazhuang, China
Key Offering: Pharmaceutical‑grade fructose for injectables and supplements

Hebei Huaxu has focused on meeting the rigorous quality requirements of the pharmaceutical sector, offering high‑purity fructose solutions that comply with global standards.

Sustainability & Growth Initiatives:

• Implementing rigorous batch consistency protocols
• Partnering with multinational pharma companies to support product development
• Investing in continuous improvement of production efficiency

---

🈚 8. Spring Young

Headquarters: Shenzhen, China
Key Offering: Crystalline fructose for pharmaceutical and nutraceutical applications

Spring Young’s strategy centers on delivering high‑purity fructose to meet the evolving needs of the pharmaceutical market, with a focus on injection and supplement use.

Sustainability & Growth Initiatives:

• Optimizing raw‑material sourcing to reduce environmental impact
• Expanding R&D for novel fructose‑based excipient solutions
• Strengthening quality management systems to support global distribution

---

🈚 9. Cargill

Headquarters: Chicago, United States
Key Offering: High‑purity fructose for pharmaceutical and nutraceutical markets

Cargill has extended its expertise in food ingredients to the pharmaceutical sector, offering crystalline fructose that meets stringent regulatory standards.

Sustainability & Growth Initiatives:

• Investing in low‑carbon processing for starch hydrolysis
• Expanding global supply chains to support regional demand
• Collaborating with pharma partners on advanced excipient development

---

🈚 10. BASF

Headquarters: Ludwigshafen, Germany
Key Offering: Pharmaceutical‑grade fructose for injection and nutrition solutions

BASF’s commitment to innovation and quality has positioned it as a reliable supplier of high‑purity fructose for the pharmaceutical industry.

Sustainability & Growth Initiatives:

• Implementing circular economy practices in production
• Developing targeted excipient solutions for specialty drugs
• Expanding capacity in key growth regions

---

Download FREE Sample Report

Get Full Report

Outlook

The crystalline fructose for pharmaceutical market is set to advance steadily as manufacturers integrate low‑glycemic excipients into a broad array of products. Regulatory momentum and the expanding scope of parenteral nutrition are expected to sustain demand, while price pressures from supply‑chain volatility will necessitate strategic sourcing and cost‑management initiatives.

Future Trends

• Integration of fructose‑based excipients into advanced drug delivery platforms, including nanoparticle and targeted therapies
• Expansion of low‑glycemic formulations across oral liquids, injectables, and nutraceuticals to meet consumer and regulatory expectations
• Adoption of continuous manufacturing and digital quality assurance to reduce production costs and enhance traceability
• Growth of regional production hubs in emerging markets to mitigate supply‑chain risk and meet local demand